-----BEGIN PRIVACY-ENHANCED MESSAGE-----
Proc-Type: 2001,MIC-CLEAR
Originator-Name: webmaster@www.sec.gov
Originator-Key-Asymmetric:
 MFgwCgYEVQgBAQICAf8DSgAwRwJAW2sNKK9AVtBzYZmr6aGjlWyK3XmZv3dTINen
 TWSM7vrzLADbmYQaionwg5sDW3P6oaM5D3tdezXMm7z1T+B+twIDAQAB
MIC-Info: RSA-MD5,RSA,
 VxovbHIJiSG+DViymYZ9XUpCu9qDayhbO4bWXYAGIyIxiUPch1uQpkTGEGesPmA8
 4r4h0HaF0rvAnR0us5ddGA==

<SEC-DOCUMENT>0000893838-05-000129.txt : 20050517
<SEC-HEADER>0000893838-05-000129.hdr.sgml : 20050517
<ACCEPTANCE-DATETIME>20050517215803
ACCESSION NUMBER:		0000893838-05-000129
CONFORMED SUBMISSION TYPE:	3
PUBLIC DOCUMENT COUNT:		2
CONFORMED PERIOD OF REPORT:	20050513
FILED AS OF DATE:		20050517
DATE AS OF CHANGE:		20050517

ISSUER:		

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			REXAHN PHARMACEUTICALS, INC.
		CENTRAL INDEX KEY:			0001228627
		STANDARD INDUSTRIAL CLASSIFICATION:	PHARMACEUTICAL PREPARATIONS [2834]
		IRS NUMBER:				113516358
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	BUSINESS ADDRESS:	
		STREET 1:		9620 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850
		BUSINESS PHONE:		2402685300

	MAIL ADDRESS:	
		STREET 1:		9620 MEDICAL CENTER DRIVE
		CITY:			ROCKVILLE
		STATE:			MD
		ZIP:			20850

	FORMER COMPANY:	
		FORMER CONFORMED NAME:	CORPORATE ROAD SHOW DOT COM INC
		DATE OF NAME CHANGE:	20030423

REPORTING-OWNER:	

	OWNER DATA:	
		COMPANY CONFORMED NAME:			Rexgene Biotech Co., Ltd.
		CENTRAL INDEX KEY:			0001316425
		STATE OF INCORPORATION:			M5
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		3
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	000-50590
		FILM NUMBER:		05840156

	BUSINESS ADDRESS:	
		STREET 1:		401 WOOYOUNG VENTURE BLDG.
		STREET 2:		SEOCHO-DONG SEOCHO-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			1330-13
		BUSINESS PHONE:		82-2 587 0019

	MAIL ADDRESS:	
		STREET 1:		401 WOOYOUNG VENTURE BLDG.
		STREET 2:		SEOCHO-DONG SEOCHO-GU
		CITY:			SEOUL
		STATE:			M5
		ZIP:			1330-13
</SEC-HEADER>
<DOCUMENT>
<TYPE>3
<SEQUENCE>1
<FILENAME>rexahnfrm3rexgene051605_ex.xml
<TEXT>
<XML>
<?xml version="1.0"?>
<ownershipDocument>

    <schemaVersion>X0202</schemaVersion>

    <documentType>3</documentType>

    <periodOfReport>2005-05-13</periodOfReport>

    <noSecuritiesOwned>0</noSecuritiesOwned>

    <issuer>
        <issuerCik>0001228627</issuerCik>
        <issuerName>REXAHN PHARMACEUTICALS, INC.</issuerName>
        <issuerTradingSymbol>RXHN</issuerTradingSymbol>
    </issuer>

    <reportingOwner>
        <reportingOwnerId>
            <rptOwnerCik>0001316425</rptOwnerCik>
            <rptOwnerName>Rexgene Biotech Co., Ltd.</rptOwnerName>
        </reportingOwnerId>
        <reportingOwnerAddress>
            <rptOwnerStreet1>401 WOOYOUNG VENTURE BLDG.</rptOwnerStreet1>
            <rptOwnerStreet2>SEOCHO-DONG SEOCHO-GU</rptOwnerStreet2>
            <rptOwnerCity>SEOUL</rptOwnerCity>
            <rptOwnerState>M5</rptOwnerState>
            <rptOwnerZipCode>1330-13</rptOwnerZipCode>
            <rptOwnerStateDescription>KOREA, REPUBLIC OF</rptOwnerStateDescription>
        </reportingOwnerAddress>
        <reportingOwnerRelationship>
            <isDirector>0</isDirector>
            <isOfficer>0</isOfficer>
            <isTenPercentOwner>1</isTenPercentOwner>
            <isOther>0</isOther>
        </reportingOwnerRelationship>
    </reportingOwner>

    <nonDerivativeTable>
        <nonDerivativeHolding>
            <securityTitle>
                <value>Common Stock</value>
                <footnoteId id="F1"/>
            </securityTitle>
            <postTransactionAmounts>
                <sharesOwnedFollowingTransaction>
                    <value>4791670</value>
                </sharesOwnedFollowingTransaction>
            </postTransactionAmounts>
            <ownershipNature>
                <directOrIndirectOwnership>
                    <value>D</value>
                </directOrIndirectOwnership>
            </ownershipNature>
        </nonDerivativeHolding>
    </nonDerivativeTable>

    <footnotes>
        <footnote id="F1">These shares were acquired pursuant to the Agreement and Plan of Merger (the &quot;Merger Agreement&quot;) among the Issuer, Rexahn,
Corp and the wholly-owned subsidiaries of the Issuer, whereby each share of Rexahn, Corp's common stock was converted into
the right to receive five shares of the Issuer's common stock.</footnote>
    </footnotes>

    <remarks>Ted T.H. Jeong is signing on behalf of Rexgene Biotech Co., Ltd. pursuant to a power of attorney filed as an Exhibit hereto.</remarks>

    <ownerSignature>
        <signatureName>/s/ Ted T.H. Jeong as attorney-in-fact for Rexgene Biotech Co., Ltd.</signatureName>
        <signatureDate>2005-05-17</signatureDate>
    </ownerSignature>
</ownershipDocument>
</XML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-24
<SEQUENCE>2
<FILENAME>poarexgene.txt
<TEXT>

                                POWER OF ATTORNEY


         The undersigned, as a Section 16 and Section 13(d) reporting person of
Rexahn Pharmaceuticals, Inc. (the "Company"), hereby constitutes and appoints
each of Ted T.H. Jeong, Chang H. Ahn and Inok Ahn the undersigned's true and
lawful attorneys-in-fact to:

         1.   Complete and execute forms and schedules and all amendments
thereto as such attorneys-in-fact shall in their discretion determine to be
required or advisable pursuant to Sections 16 and 13(d) of the Securities
Exchange Act of 1934 (as amended) and the rules and regulations promulgated
thereunder, or any successor laws and regulations, as a consequence of the
undersigned's ownership, acquisition or disposition of securities of the
Company; and

         2.   Do all acts necessary in order to file such forms and schedules
with the Securities and Exchange Commission, any securities exchange or national
association, the Company and such other person or agency as the
attorneys-in-fact shall deem appropriate.

         The undersigned hereby ratifies and confirms all that said
attorneys-in-fact and agent shall do or cause to be done by virtue hereof. The
undersigned acknowledges that the foregoing attorneys-in-fact, in serving in
such capacity at the request of the undersigned, are not assuming, nor is the
Company assuming, any of the undersigned's responsibilities to comply with
Sections 16 and 13(d) of the Securities Exchange Act of 1934 (as amended).

         This Power of Attorney shall remain in full force and effect until the
undersigned is no longer required to file forms and schedules with respect to
the undersigned's holdings of and transactions in securities issued by the
Company, unless earlier revoked by the undersigned in a signed writing delivered
to the Company and the foregoing attorneys-in-fact.

         IN WITNESS WHEREOF, the undersigned has caused this Power of Attorney
to be executed as of this 16th day of May, 2005.


            Signature                                        Date
            ---------                                        ----


By : /s/ S. H. Kwon                                           May 16, 2005
- ------------------------------
Name: Rexgene Biotech Co., Ltd.
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
-----END PRIVACY-ENHANCED MESSAGE-----
